FDA Approves Umeclidinium for COPD Treatment

The U.S. Food and Drug Administration has approved GlaxoSmithKline's Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report.

Incruse Ellipta is intended as a once-daily maintenance treatment to be administered via GSK's Ellipta inhaler.

GSK plans to begin distributing the drug in the fourth quarter of this year.

More Articles on FDA Approvals:

FDA Grants Accelerated Approval to Lung Cancer Treatment Drug
FDA Approves DNA Test for Primary Cervical Cancer Screening
FDA Approves First Drug to Treat Castleman's Disease

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars